Protara Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Protara Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 4 currently recruiting 3 completed early-phase tilt upper quartile by trial count

Protara Therapeutics: 7 sponsored US clinical trials, 4 recruiting.

Protara Therapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Non-muscle Invasive Bladder Cancer, with 2 trials.

Upper-quartile sponsor footprint

Protara Therapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 3

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

NCT07480356
RECRUITING Phase 2

Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support

NCT06910943
RECRUITING Phase 2

Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age

NCT05871970
RECRUITING Phase 2

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

NCT05951179
COMPLETED Phase 1

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b)

NCT05085990
COMPLETED Phase 1

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

NCT05085977
COMPLETED

Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

NCT05011370

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3
Phase 3 1

Therapeutic Areas

Non-muscle Invasive Bladder Cancer 2
Liver Injury 1
Choline Deficiency 1
Lymphatic Malformation 1

What is open in the Protara Therapeutics pipeline

4 recruiting of 7 indexed (57% open); 3 completed (43%).

Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Non-muscle Invasive Bladder Cancer (2 trials), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Protara Therapeutics: open-pipeline peers nationwide

Peers matched on 7 registered trials and 57% open enrollment, not the therapeutic-area sidebar.

Protara Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 6.97.07.077.07.07.1 0%20%40%60% Total trials Recruiting share Protara Therapeutics3M4Life Research89bioAbbott Diagnostics DivisionAlimentivAura BiosciencesBicycleTx LimitedBinghamton University
Protara Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Protara Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 57% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Protara Therapeutics page

7 registered trials is a research-attention snapshot, not an endorsement of Protara Therapeutics or any single study.

  • 4 of Protara Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Non-muscle Invasive Bladder Cancer is the condition Protara Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Non-muscle Invasive Bladder Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Protara Therapeutics pipeline card: 7 registered trials from official public datasets.Report a data error.